Company
transitionbio
Redefining drug discovery at the molecular level
Also known as Transition Bio
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- transitionbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
By combining the technology and data engine of Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab, we created the only end-to-end condensate drug discovery platform built on molecular insights.
Funding snapshot
- Total raised
- $58.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Series A, $50M2022-06-02
Funding rounds
- Round, 2024
- $13.3M2024-10-11, SEC form D sold, 8 investors
- Round, 2023
- $6M2023-12-22, SEC form D sold, 5 investors
- Series A
- $50M2022-06-02, Company stated
- Round, 2022
- $39.1M2022-03-24, SEC form D sold, 23 investors
- Seed
- 2020-11-30
Loading relationship preview